Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic derivative of leucine known as 2-(acetyl-hydroxy-amino)-4-methyl-pentanoic acid methyl ester. It is classified as a small molecule and belongs to the class of leucine derivatives. The structure features an acetylated and N-hydroxylated amino group on the D-enantiomer of leucine with a terminal carboxylic acid group converted to its methyl ester form. There are no approved therapeutic indications or clinical trial data available for this compound; it is considered experimental and has not been developed for any specific disease or condition[1][2][3]. No mechanism of action or pharmacological activity has been described in public databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(acetyl-hydroxy-amino)-4-methyl-pentanoic acid methyl ester.